Press Release

– Industry veteran strengthens Pyxis team with expertise in clinical development, medical affairs and antibody-drug conjugates (ADCs) – CAMBRIDGE, Mass., Sept. 14, 2021 – Pyxis Oncology (“Pyxis” or the “Company”) today announced the appointment of Jay M. Feingold, M.D., Ph.D., as Chief Medical Officer. “Jay’s track record of success taking oncology ADC programs from discovery […]

–  Seasoned industry executives add significant operating experience to Pyxis’ Board of Directors – CAMBRIDGE, Mass., Sept. 7, 2021 – Pyxis Oncology (“Pyxis” or the “Company”) today announced the appointments of Freda Lewis-Hall, M.D., Thomas Civik, Darren Cline, and Mark Chin to its Board of Directors. These strategic appointments strengthen the company’s operational, clinical, and

– Veteran biotech executive adds financial and operational expertise to growing Pyxis team – CAMBRIDGE, Mass., August 31, 2021 – Pyxis Oncology (“Pyxis” or the “Company”) today announced the recent appointment of Pamela Yanchik Connealy, M.B.A., as its Chief Financial Officer.  Ms. Connealy will be leading the Finance, Investor Relations and Human Resources functions at

– Steve Monks, Ph.D., appointed as Chief Technical Officer, brings 20+ years in drug development and CMC, Quality, and Regulatory operations –– Ritu Shah, PMP, appointed as Chief Operating Officer, brings 20+ years of industry experience specializing in portfolio management and strategic planning –– Christoph Rader, Ph.D., and Anthony W. Tolcher, M.D., join Scientific Advisory

LEXINGTON & CAMBRIDGE, Mass., May 25, 2021 – Alloy Therapeutics (“Alloy”) and Pyxis Oncology (“Pyxis”) today announced the formation of a joint venture named Kyma Therapeutics to develop immune-modulating antibodies for novel targets in cancer and autoimmune diseases. Kyma Therapeutics will advance programs directed to immune-modulating targets identified by Pyxis. Alloy Discovery Services will generate

— Pyxis Oncology to host webcast with Key Opinion Leaders (KOLs) on April 27, 2021 at 1:00pm ET — CAMBRIDGE, Mass., April 27, 2021 – Pyxis Oncology (“Pyxis” or the “Company”) today announced the targets of its three antibody-drug conjugate (ADC) candidates along with additional details and preclinical data supporting the potential of its ADC

Webinar on Tuesday, April 27th @ 1pm ET CAMBRIDGE, Mass., April 19, 2021 – Pyxis Oncology (“Pyxis” or the “Company”) today announced that it will host a key opinion leader (KOL) webinar on antibody-drug conjugates on Tuesday, April 27, 2021 at 1pm Eastern Time. Also featured will be a presentation by Pyxis Oncology Chief Executive

— New round enables Pyxis to advance differentiated antibody-drug conjugate (ADC) and immuno-oncology (I/O) programs to next value inflection point —— In addition to recently announced in-licensed ADC candidates and ADC toolkit from Pfizer, funding to support in-licensed ADC candidate from LegoChem Biosciences — CAMBRIDGE, Mass., March, 30, 2021 – Pyxis Oncology (“Pyxis” or the

— Pyxis expands developmental capabilities with license to two ADC programs and ADC technology platform toolkit developed by Pfizer — CAMBRIDGE, Mass., March 18, 2021 – Pyxis Oncology (“Pyxis” or the “Company”) today announced that it has entered into a worldwide license agreement with Pfizer Inc. (NYSE:PFE) for the development and commercialization of two antibody-drug

Boston, Mass., December 11, 2019  – Pyxis Oncology, an immuno-oncology company focused on developing a new family of antibody-based immunotherapies derived from novel insights into the biology of the tumor microenvironment, today announced the appointment of Lara Sullivan, M.D. as Chief Executive Officer and Director. She succeeds Longwood General Partner and founding Chief Executive Officer David Steinberg,